Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.
From 2010 onwards, the patents of many major biopharmaceuticals will expire, paving the way for competition. Also, it is estimated that by 2010 some 50% of newly approved medicines will be biopharmaceuticals. All of these will eventually face patent expiry. In other words, biosimilars are a major future market for companies like Sandoz.
